97 related articles for article (PubMed ID: 30679798)
1. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
Krombholz CF; Gallego-Villar L; Sahoo SS; Panda PK; Wlodarski MW; Aumann K; Hartmann M; Lipka DB; Daskalakis M; Plass C; Niemeyer CM; Erlacher M; Flotho C
Leukemia; 2019 Jul; 33(7):1805-1810. PubMed ID: 30679798
[No Abstract] [Full Text] [Related]
2. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
3. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine as a bridge to transplantation in juvenile myelomonocytic leukemia.
Takebayashi A; Yamamoto M; Igarashi K; Muramatsu H; Kawasaki Y
Pediatr Int; 2022 Jan; 64(1):e14929. PubMed ID: 35119175
[No Abstract] [Full Text] [Related]
5. Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Matsuda K; Nakazawa Y; Iwashita C; Kurata T; Hirabayashi K; Saito S; Tanaka M; Yoshikawa K; Yanagisawa R; Sakashita K; Sasaki S; Honda T; Koike K
Leukemia; 2014 Jul; 28(7):1545-8. PubMed ID: 24496301
[No Abstract] [Full Text] [Related]
6. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
Cseh A; Niemeyer CM; Yoshimi A; Dworzak M; Hasle H; van den Heuvel-Eibrink MM; Locatelli F; Masetti R; Schmugge M; Groß-Wieltsch U; Candás A; Kulozik AE; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
Blood; 2015 Apr; 125(14):2311-3. PubMed ID: 25838281
[No Abstract] [Full Text] [Related]
7. ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells.
Takahashi N; Nobusue H; Shimizu T; Sugihara E; Yamaguchi-Iwai S; Onishi N; Kunitomi H; Kuroda T; Saya H
Cancer Res; 2019 Jun; 79(12):3088-3099. PubMed ID: 30992323
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth.
Pathania R; Ramachandran S; Mariappan G; Thakur P; Shi H; Choi JH; Manicassamy S; Kolhe R; Prasad PD; Sharma S; Lokeshwar BL; Ganapathy V; Thangaraju M
Cancer Res; 2016 Jun; 76(11):3224-35. PubMed ID: 27197203
[TBL] [Abstract][Full Text] [Related]
10. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Fujikawa A; Sugawara H; Tanaka T; Matsumoto M; Kuboyama K; Suzuki R; Tanga N; Ogata A; Masumura M; Noda M
Sci Rep; 2017 Jul; 7(1):5609. PubMed ID: 28717188
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene.
Zhang L; Wen X; Li M; Li S; Zhao H
Biofactors; 2018 Jan; 44(1):61-68. PubMed ID: 29205560
[TBL] [Abstract][Full Text] [Related]
12. Casticin suppresses the carcinogenesis of small cell lung cancer H446 cells through activation of AMPK/FoxO3a signaling.
Gong Q; Cao X; Cao J; Yang X; Zeng W
Oncol Rep; 2018 Sep; 40(3):1401-1410. PubMed ID: 30015975
[TBL] [Abstract][Full Text] [Related]
13. Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-/-γc-/- mice.
Krombholz CF; Aumann K; Kollek M; Bertele D; Fluhr S; Kunze M; Niemeyer CM; Flotho C; Erlacher M
Haematologica; 2016 May; 101(5):597-606. PubMed ID: 26888021
[TBL] [Abstract][Full Text] [Related]
14. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.
Nawrocki ST; Han Y; Visconte V; Przychodzen B; Espitia CM; Phillips J; Anwer F; Advani A; Carraway HE; Kelly KR; Sekeres MA; Maciejewski JP; Carew JS
Leukemia; 2019 Dec; 33(12):2971-2974. PubMed ID: 31358855
[No Abstract] [Full Text] [Related]
15. Central nervous system lesions due to juvenile myelomonocytic leukemia progressed in a boy undergoing first line chemotherapy.
Fukushima H; Fukushima T; Hiraki A; Suzuki R; Mahmoud SS; Yoshimi A; Nakao T; Kato K; Kobayashi C; Koike K; Fukasawa M; Morishita Y; Doisaki S; Muramatsu H; Sumazaki R
Int J Hematol; 2012 May; 95(5):581-4. PubMed ID: 22461033
[TBL] [Abstract][Full Text] [Related]
16. Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.
Calkoen FG; Vervat C; Eising E; Vijfhuizen LS; 't Hoen PB; van den Heuvel-Eibrink MM; Egeler RM; van Tol MJ; Ball LM
Haematologica; 2015 Nov; 100(11):1434-41. PubMed ID: 26294732
[TBL] [Abstract][Full Text] [Related]
17. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
18. Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497.
Liu L; Chen L; Wu X; Li X; Song Y; Mei Q; Nie J; Han W
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1431-9. PubMed ID: 27075177
[TBL] [Abstract][Full Text] [Related]
19. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
Guillaume T; Dehame V; Chevallier P; Peterlin P; Garnier A; Grégoire M; Pichinuk E; Rubinstein DB; Wreschner DH
Exp Hematol; 2019 Feb; 70():97-108. PubMed ID: 30593830
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.
Wang J; Luo B; Li X; Lu W; Yang J; Hu Y; Huang P; Wen S
Cell Death Dis; 2017 Jun; 8(6):e2887. PubMed ID: 28640251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
